Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (DE:4AJ0)
:4AJ0
Earnings Data
Report Date
Aug 21, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.17Last Year’s EPS
0.12Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 5.42%
|Next Earnings Date:Aug 21, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for ALK, highlighting strong revenue and earnings growth, supported by successful tablet sales and strategic advancements in the pediatric segment. Despite challenges in China, the company maintains its full-year outlook with confidence.Company Guidance
In the recent earnings call, ALK reported solid Q1 2025 results, with revenue increasing by 12% to DKK 1.5 billion, led by a 22% growth in global tablet sales. North America saw a 14% sales increase, while Europe experienced a 10% growth, driven by tablet sales rising 17%. The EBIT margin improved to 31%, with earnings up 50% to DKK 469 million due to optimization initiatives saving over DKK 300 million. International markets also showed robust growth, particularly with a 41% increase in tablet revenue. The company maintained its full-year outlook, projecting a 9% to 13% revenue rise, driven by double-digit tablet sales growth. Despite global trade concerns, ALK expects minimal impact and continues to focus on strategic priorities, including pediatric market expansion and partnerships like the neffy collaboration.Strong Revenue Growth
Revenue grew by 12% to DKK 1.5 billion, with all sales regions experiencing double-digit growth. North America showed a significant recovery with 14% growth.
Tablet Sales Performance
Global tablet sales increased by 22%, largely driven by higher volumes and shipments to Torii in Japan. The house dust mite tablet, ACARIZAX, performed well, particularly in Europe and North America.
Earnings Improvement
Earnings improved by 50% to DKK 469 million, resulting in an EBIT margin of 31%. This was achieved despite market turmoil, helped by optimization initiatives saving DKK 300 million.
Pediatric Segment Growth
The new pediatric indications for house dust mite tablets resulted in higher-than-expected initial market uptake, surpassing expectations with over 1,000 prescribers initiating treatment.
Strong Cash Flow
Free cash flow almost tripled to DKK 330 million, with the net debt-to-EBITDA ratio decreasing, indicating a stronger balance sheet.
---
DE:4AJ0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:4AJ0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | €21.04 | €22.00 | +4.56% |
Feb 19, 2025 | €20.84 | €20.82 | -0.10% |
Nov 14, 2024 | €21.54 | €22.80 | +5.85% |
Aug 22, 2024 | €21.42 | €21.30 | -0.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ALK-abello A/S Class B (DE:4AJ0) report earnings?
ALK-abello A/S Class B (DE:4AJ0) is schdueled to report earning on Aug 21, 2025, TBA Not Confirmed.
What is ALK-abello A/S Class B (DE:4AJ0) earnings time?
ALK-abello A/S Class B (DE:4AJ0) earnings time is at Aug 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of ALK-abello A/S Class B stock?
The P/E ratio of ALK-abello is N/A.
What is DE:4AJ0 EPS forecast?
DE:4AJ0 EPS forecast for the fiscal quarter 2025 (Q2) is 0.17.
---